|
[Greeting] [Title] [Name],
|
|
It was a pleasure speaking with you. I enjoyed hearing your thoughts on the challenges faced by you and your patients with Parkinson’s disease (PD). A few things to keep in mind:
|
|
|
|
Carbidopa/levodopa (CD/LD) is the gold standard foundational treatment for PD1,2
|
|
|
|
|
|
Despite nearly 1 million people affected, current treatments don’t fully address the unique needs of patients with PD2-4
|
|
|
|
|
|
While no two patients are the same, the burden all patients face is significant
|
|
|
|
|
|
Avion is committed to providing patients with a more personalized CD/LD experience
|
|
|
| |
|
If you have any further questions, don’t hesitate to reach out. I look forward to connecting with you soon. In the meantime, click the button below to learn more about Avion and our efforts.
|
|
Face a brighter future
|
|
Feel free to reach me at:
|
|
[rep email] | [rep phone number]
|
|
Sincerely,
|
|
[rep name]
|
|
[rep title]
|
|
[rep photo]
|
|
|
References: 1. Olanow CW, Calabresi P, Obeso JA. Continuous dopaminergic stimulation as a treatment for Parkinson’s disease: current status and future opportunities. Mov Disord. 2020;35(10):1731-1744. doi:10.1002/mds.28215.
2. Tanner CM. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 suppl):S255-S264. doi:10.37765/ajmc.2020.88517. 3. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. doi:10.1038/s41531-020-0117-1. 4. Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018.
|
|
|
